New AI model helps make accurate diagnoses of biliary atresia
A new artificial intelligence (AI) model based on clinical data along with laboratory results and ultrasound images aids the early diagnosis of biliary atresia,…
Steve Bryson, PhD, Science Writer — 
Articles by Steve Bryson
Researchers ID mechanism behind severe ABCB11 mutations in PFIC2
Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…
LiverMultiScan may lessen need for biopsy in assessing MASLD
Perspectum‘s MRI-based LiverMultiScan improves the diagnostic rate of metabolic dysfunction-associated steatotic liver disease (MASLD) — a form of fatty liver disease —…
Phase 3 trial of hepatitis D treatment combo enrolls 1st patient
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
Researchers uncover how hepatitis B virus can persist in liver cells
Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…
Researchers develop tool to predict drug-induced cholestasis
Researchers have developed a tool that can distinguish medications that result in cholestasis from those that don’t, based on their effects on key bile…
6 JAG1, NOTCH2 gene mutations ID’d as likely cause of Alagille
Researchers in China have identified six new mutations in the JAG1 and NOTCH2 genes as likely causes of Alagille syndrome. In…
Hepatitis C telemedicine approach for opioid users receives award
A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…
2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
